Research progress of STC2 in breast cancer

Xuezhi Niu; Yong Zhan; Suhua Zhang; Zixin Liu; Chang Qu

doi:10.52601/bpr.2021.210002

Volume 7 Issue 3

Jun. 2021

Turn off MathJax

Article Contents

Article Navigation > Biophysics Reports > 2021 > 7(3): 185-192

Xuezhi Niu, Yong Zhan, Suhua Zhang, Zixin Liu, Chang Qu. Research progress of STC2 in breast cancer. Biophysics Reports, 2021, 7(3): 185-192. doi: 10.52601/bpr.2021.210002

Citation:

Xuezhi Niu, Yong Zhan, Suhua Zhang, Zixin Liu, Chang Qu. Research progress of STC2 in breast cancer. Biophysics Reports, 2021, 7(3): 185-192. doi: 10.52601/bpr.2021.210002

Xuezhi Niu, Yong Zhan, Suhua Zhang, Zixin Liu, Chang Qu. Research progress of STC2 in breast cancer. Biophysics Reports, 2021, 7(3): 185-192. doi: 10.52601/bpr.2021.210002

Citation:

Xuezhi Niu, Yong Zhan, Suhua Zhang, Zixin Liu, Chang Qu. Research progress of STC2 in breast cancer. Biophysics Reports, 2021, 7(3): 185-192. doi: 10.52601/bpr.2021.210002

PDF (387 KB)

Research progress of STC2 in breast cancer

doi: 10.52601/bpr.2021.210002

1.
Key Laboratory of Hebei Province for Molecular Biophysics, Institute of Biophysics, School of Science, Hebei University of Technology, Tianjin 300401, China

Funds: Our coworkers have made great contribution to this work herein and we are grateful to them. This research was funded by National Natural Science Foundation of China (11735006).

More Information

Corresponding author: zhangsuhua76@163.com (S. Zhang)
Received Date: 01 February 2021
Accepted Date: 16 March 2021

Available Online: 07 July 2021

Publish Date: 30 June 2021

Abstract

Abstract

Breast cancer ranks second in the list of most common cancers among women and brings the double burden of economy and health to women. Therefore, it is an urgent and necessary task to study the pathogenic mechanism and the treatment of breast cancer. Glycoprotein hormone is a kind of hormones to promote the growth and the development of cell and stanniocalcin 2 (STC2) is one of them. Research has shown us a various expression of SCT2 in organs and tissues and it can regulate many different pathological and physiological processes. In addition, there are a lot of previous studies that indicated a close correlation between STC2 and the development and metastasis of many cancers, which infers STC2 can serve as biomarker of certain cancers. Until now, the effects of STC2 on breast cancer have been studied widely, but research findings demonstrated two different views, one view is that STC2 plays an oncogenic role and the other is the opposite. In this paper, it will summarize and evaluate the research data and results about mammalian STC2 on breast cancer.
- Breast cancer,
- Stanniocalcin 2 (STC2),
- Invasion,
- Metastasis,
- Prognosis,
- Proliferation

FullText(HTML)

References(55)

References

[1]	Arigami T, Uenosono Y, Ishigami S, Yanagita S, Hagihara T, Haraguchi N, Matsushita D, Hirahara T, Okumura H, Uchikado Y (2013) Clinical significance of stanniocalcin 2 expression as a predictor of tumor progression in gastric cancer. Oncol Rep 30(6): 2838−2844 doi: 10.3892/or.2013.2775
[2]	Block GJ, Ohkouchi S, Fung F, Frenkel J, Gregory C, Pochampally R, DiMattia G, Sullivan DE, Prockop DJ (2009) Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. Stem Cells 27(3): 670−681 doi: 10.1002/stem.20080742
[3]	Borniger JC (2019) Central regulation of breast cancer growth and metastasis. J Cancer Metastasis Treat 5: 23. https://doi.org/10.20517/2394-4722.2018
[4]	Bouras T, Southey MC, Chang AC, Reddel RR, Venter DJ (2002) Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res 62(5): 1289−1295
[5]	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6): 394−424 doi: 10.3322/caac.21492
[6]	Chang AC, Janosi J, Hulsbeek M, de Jong D, Jeffrey KJ, Noble JR, Reddel RR (1995) A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol 112(2): 241−247 doi: 10.1016/0303-7207(95)03601-3
[7]	Chang AC, Jeffrey KJ, Tokutake Y, Shimamoto A, Neumann AA, Dunham MA, Cha J, Sugawara M, Furuichi Y, Reddel RR (1998) Human stanniocalcin (STC): genomic structure, chromosomal localization, and the presence of CAG trinucleotide repeats. Genomics 47(3): 393−398 doi: 10.1006/geno.1997.5120
[8]	Chang CM, Reddel RR (1998b) Identification of a second stanniocalcin cDNA in mouse and human: stanniocalcin 2. Mol Cell Endocrinol 141(1-2): 95−99 doi: 10.1016/S0303-7207(98)00097-5
[9]	Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC, Aldaz CM (2000) Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res 60(21): 5977−5983
[10]	Ching-Wei L, Pisarska MD, Hsueh AJW (2005) Identification of a stanniocalcin paralog, stanniocalcin-2, in fish and the paracrine actions of stanniocalcin-2 in the mammalian ovary. Endocrinology 1: 469−476
[11]	Coulson-Gilmer C, Humphries MP, Sundara Rajan S, Droop A, Jackson S, Condon A, Cserni G, Jordan LB, Jones LJ, Kanthan R, Di Benedetto A, Mottolese M, Provenzano E, Kulka J, Shaaban AM, Hanby AM, Speirs V (2018) Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. J Pathol Clin Res 4(4): 241−249 doi: 10.1002/cjp2.106
[12]	De Abreu FB, Wells WA, Tsongalis GJ (2013) The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. Am J Pathol 183(4): 1075−1083 doi: 10.1016/j.ajpath.2013.07.002
[13]	Di S, Lu D, Chen C, Ma T, Zou Z, Zhang Z (2020) Long non-coding RNA MAFG-AS1 promotes proliferation and metastasis of breast cancer by modulating STC2 pathway. Res Square. https://doi.org/10.21203/rs.3.rs-16997/v1
[14]	Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, Reis-Filho JS, Isacke CM (2007) Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin Cancer Res 13(11): 3164−3173 doi: 10.1158/1078-0432.CCR-07-0224
[15]	Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, Mankaruos M, Youssef Y, Khalil B, Khella H, Pasic M, Yousef GM (2012) Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res 72(20): 5273−5284 doi: 10.1158/0008-5472.CAN-12-0656
[16]	Greenwood MP, Flik G, Wagner GF, Balment RJ (2009) The corpuscles of Stannius, calcium-sensing receptor, and stanniocalcin: responses to calcimimetics and physiological challenges. Endocrinology 150(7): 3002−3010 doi: 10.1210/en.2008-1758
[17]	Hou J, Wang Z, Xu H, Yang L, Yu X, Yang Z, Deng Y, Meng J, Feng Y, Guo X, Yang G (2015) Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling. PLoS One 10(4): e0122179. https://doi.org/10.1371/journal.pone.0122179
[18]	Ieta K, Tanaka F, Yokobori T, Kita Y, Haraguchi N, Mimori K, Kato H, Asao T, Inoue H, Kuwano H, Mori M (2009) Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer 125(4): 926−931 doi: 10.1002/ijc.24453
[19]	Ishibashi K, Miyamoto K, Taketani Y, Morita K, Takeda E, Sasaki S, Imai M (1998) Molecular cloning of a second human stanniocalcin homologue (STC2). Biochem Biophys Res Commun 250(2): 252−258 doi: 10.1006/bbrc.1998.9300
[20]	James K, Seitelbach M, Mccudden CR, Wagner GF (2005) Evidence for stanniocalcin binding activity in mammalian blood and glomerular filtrate. Kidney Int 67(2): 477−482 doi: 10.1111/j.1523-1755.2005.67104.x
[21]	Jansen MP, Sas L, Sieuwerts AM, Van Cauwenberghe C, Ramirez-Ardila D, Look M, Ruigrok-Ritstier K, Finetti P, Bertucci F, Timmermans MM, van Deurzen CH, Martens JW, Simon I, Roepman P, Linn SC, van Dam P, Kok M, Lardon F, Vermeulen PB, Foekens JA, Dirix L, Berns EM, Van Laere S (2015) Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. Mol Oncol 9(6): 1218−1233 doi: 10.1016/j.molonc.2015.02.006
[22]	Jiang W (2000) The distribution of stanniocalcin 1 protein in fetal mouse tissues suggests a role in bone and muscle development. J Endocrinol 165(2): 457−466 doi: 10.1677/joe.0.1650457
[23]	Jiang ST, Wang HQ, Yang TC, Wang DW, Yang LJ, Xi YQ, Kong FZ, Pan XK, Xu LH, Feng MH, Xie W, Su F (2019) Expression of stanniocalcin 2 in breast cancer and its clinical significance. Curr Med Sci 39(6): 978−983 doi: 10.1007/s11596-019-2131-2
[24]	Kahn J, Mehraban F, Ingle G, Xin X, Bryant JE, Vehar G, Schoenfeld J, Grimaldi CJ, Peale F, Draksharapu A, Lewin DA, Gerritsen ME (2000) Gene expression profiling in an in vitro model of angiogenesis. Am J Pathol 156(6): 1887−1900 doi: 10.1016/S0002-9440(10)65062-6
[25]	Law AY, Lai KP, Ip CK, Wong AS, Wagner GF, Wong CK (2008) Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Exp Cell Res 314(8): 1823−1830 doi: 10.1016/j.yexcr.2008.03.001
[26]	Law AY, Wong CK (2010a) Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res 316(3): 466−476 doi: 10.1016/j.yexcr.2009.09.018
[27]	Law AY, Wong CK (2010b) Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res 316(20): 3425−3434 doi: 10.1016/j.yexcr.2010.06.026
[28]	Li L, Wong CK (2008) Effects of dexamethasone and dibutyryl cAMP on stanniocalcin-1 mRNA expression in rat primary Sertoli and Leydig cells. Mol Cell Endocrinol 283(1-2): 96−103 doi: 10.1016/j.mce.2007.11.028
[29]	Lin S, Guo Q, Wen J, Li C, Lin J, Cui X, Sang N, Pan J (2014) Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas. J Exp Clin Cancer Res 33(1): 26. https://doi.org/10.1186/1756-9966-33-26
[30]	Liu R, Wei S, Chen J, Xu S (2014) Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications. Cancer Lett 353(2): 145−152 doi: 10.1016/j.canlet.2014.07.047
[31]	Lu W, Kang Y (2019) Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell 49(3): 361−374 doi: 10.1016/j.devcel.2019.04.010
[32]	McCudden CR (2002) Characterization of mammalian stanniocalcin receptors mitochondrial targeting of ligand and receptor for regulation of cellular metabolism. J Bioll Chem 277(47): 45249−45258 doi: 10.1074/jbc.M205954200
[33]	Moore EE, Kuestner RE, Conklin DC, Whitmore TE, Downey W, Buddle MM, Adams RL, Bell LA, Thompson DL, Wolf A, Chen L, Stamm MR, Grant FJ, Lok S, Ren H, De Jongh KS (1999) Stanniocalcin 2: characterization of the protein and its localization to human pancreatic alpha cells. Horm Metab Res 31(7): 406−414 doi: 10.1055/s-2007-978764
[34]	Murai R, Tanaka M, Takahashi Y, Kuribayashi K, Kobayashi D, Watanabe N (2014) Stanniocalcin-1 promotes metastasis in a human breast cancer cell line through activation of PI3K. Clin Exp Metastasis 31(7): 787−794 doi: 10.1007/s10585-014-9668-z
[35]	Okabe H, Satoh S, Kato T, Kitahara O, Nakamura Y (2001) Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61(5): 2129−2137
[36]	Paciga M, Hirvi ER, James K, Wagner GF (2005) Characterization of big stanniocalcin variants in mammalian adipocytes and adrenocortical cells. Am J Physiol Endocrinol Metab 289(2): E197−205 doi: 10.1152/ajpendo.00581.2004
[37]	Paciga M, McCudden CR, Londos C, DiMattia GE, Wagner GF (2003) Targeting of big stanniocalcin and its receptor to lipid storage droplets of ovarian steroidogenic cells. J Biol Chem 278(49): 49549−49554 doi: 10.1074/jbc.M307302200
[38]	Parris TZ, Kovács A, Aziz L, Hajizadeh S, Nemes S, Semaan M, Forssell-Aronsson E, Karlsson P, Helou K (2014) Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma. Int J Cancer 134(7): 1617−1629 doi: 10.1002/ijc.28497
[39]	Pierson PM, Lamers A, Flik G, Mayer-Gostan N (2004) The stress axis, stanniocalcin, and ion balance in rainbow trout. Gen Comp Endocrinol 137(3): 263−271 doi: 10.1016/j.ygcen.2004.03.010
[40]	Raulic S, Ramos-Valdes Y, Dimattia GE (2008) Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro. J Endocrinol 197(3): 517−529 doi: 10.1677/JOE-08-0043
[41]	Shirakawa M, Fujiwara Y, Sugita Y, Moon JH, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Mori M, Doki Y (2012) Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma. Oncol Rep 27(4): 940−946 doi: 10.3892/or.2011.1607
[42]	Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1): 7−30 doi: 10.3322/caac.21590
[43]	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19): 10869−10874 doi: 10.1073/pnas.191367098
[44]	Stebbing J, Filipović A, Giamas G (2013) Claudin-1 as a promoter of EMT in hepatocellular carcinoma. Oncogene 32(41): 4871−4872 doi: 10.1038/onc.2012.591
[45]	Su J, Guo B, Zhang T, Wang K, Li X, Liang G (2015) Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients. Tumour Biol 36(8): 6333−6339 doi: 10.1007/s13277-015-3319-0
[46]	Tamura K, Furihata M, Chung SY, Uemura M, Yoshioka H, Iiyama T, Ashida S, Nasu Y, Fujioka T, Shuin T, Nakamura Y, Nakagawa H (2009) Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci 100(5): 914−919 doi: 10.1111/j.1349-7006.2009.01117.x
[47]	Todd JR, Ryall KA, Vyse S, Wong JP, Natrajan RC, Yuan Y, Tan AC, Huang PH (2016) Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. Oncotarget 7(39): 62939−62953 doi: 10.18632/oncotarget.11307
[48]	Volland S, Kugler W, Schweigerer L, Wilting J, Becker J (2009) Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma. Int J Cancer 125(9): 2049−2057 doi: 10.1002/ijc.24564
[49]	Wascher RA, Huynh KT, Giuliano AE, Hansen NM, Singer FR, Elashoff D, Hoon DS (2003) Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. Clin Cancer Res 9(4): 1427−1435 doi: 10.1093/carcin/bgg048
[50]	Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, Warrington JA, King MC (2002) BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA 99(11): 7560−7565 doi: 10.1073/pnas.062181799
[51]	White KE, Biber J, Murer H, Econs MJ (1998) Chromosomal localization of two human genes involved in phosphate homeostasis: the type IIb sodium-phosphate cotransporter and stanniocalcin-2. Somat Cell Mol Genet 24(6): 357−362 doi: 10.1023/A:1024442524808
[52]	Wu J, Lai M, Shao C, Wang J, Wei JJ (2015) STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer. Oncol Rep 34(3): 1494−1502 doi: 10.3892/or.2015.4120
[53]	Yang S, Ji Q, Chang B, Wang Y, Zhu Y, Li D, Huang C, Wang Y, Sun G, Zhang L, Guan Q, Xiang J, Wei W, Lu Z, Liao T, Meng J, Wang Z, Ma B, Zhou L, Wang Y, Yang G (2017) STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling. Oncotarget 8(4): 5976−5991 doi: 10.18632/oncotarget.13355
[54]	Zhang K, Lindsberg PJ, Tatlisumak T, Kaste M, Olsen HS, Andersson LC (2000) Stanniocalcin: a molecular guard of neurons during cerebral ischemia. Proc Natl Acad Sci USA 97(7): 3637−3642 doi: 10.1073/pnas.97.7.3637
[55]	Zhang KZ, Westberg JA, Paetau A, von Boguslawsky K, Lindsberg P, Erlander M, Guo H, Su J, Olsen HS, Andersson LC (1998) High expression of stanniocalcin in differentiated brain neurons. Am J Pathol 153(2): 439−445 doi: 10.1016/S0002-9440(10)65587-3